Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium

Transplantation

Volumn 86, Issue 4, 2008, Pages 548-553

  Augustine, Joshua J ^a,b   Rodriguez, Victoria ^a   Padiyar, Aparna ^a   Bodziak, Kenneth A ^a   Schulak, James A ^a   Hricik, Donald E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE   (United States)

Author keywords

Anemia; Enteric coated mycophenolate sodium; Kidney transplantation; Sirolimus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GANCICLOVIR; HEMOGLOBIN; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSFERRIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; ERYTHROCYTE; ERYTHROCYTOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ANEMIA; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; IMMUNOLOGY; KIDNEY FUNCTION TEST; METABOLISM; PHYSIOLOGY;

ANEMIA; DRUG RESISTANCE; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; SIROLIMUS; TABLETS, ENTERIC-COATED;

EID: 52449124228     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181814a96     Document Type: Article

References (28)

1. Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepide-miology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004; 15: 1347.
2. Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429.
3. Imoagene-Oyedeji AE, Rosas SE, Doyle AM, et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: Risk factors and implications for mortality. J Am Soc Nephrol 2006; 17: 3240.
4. Mix TC, Kazmi W, Khan S, et al. Anemia: A continuing problem following kidney transplantation. Am J Transplant 2003; 3: 1426.
5. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001.
6. Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: Prevalence and predictors. Transplantation 2006; 81: 1112.
7. Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients - A prospective cohort study. Am J Transplant 2007; 7: 731.
8. Roman J, Wheby MS, Atuk NO, et al. Anemias with renal transplantation. JAMA 1972; 221: 1283.
9. European Mycophenolate Mofetil Cooperative Study Group. My-cophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391.
10. Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant eryth-rocytosis. Kidney Int 2003; 63: 1187.
11. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89: 1052.
12. Hutchinson RE, Davey FR. Hematopoiesis, clinical diagnosis and management by laboratory methods. Henry JB (editor-in-chief), [ed 19]. WB, Saunders, 1996.
13. Levey AS, Bosch JP, Lewis JB, et al.A more accurate methodto estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
14. Montanaro D, Gropuzzo M, Tulissi P, et al. Effects of mycophenolate mofetil and azathioprine on the erythropoietin production in renal transplant recipients. Transplant Proc 2001; 33: 3253.
15. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmaco-dynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888.
16. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycopheno-late sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
17. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237.
18. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000; 53: S2.
19. Moulin B, Ollier J, George F, et al. Serum erythropoietin and reticulocyte maturity index after renal transplantation: A prospective longitudinal study. Nephron 1995; 69: 259.
20. Bouscary D, Pene F, Glaessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436.
21. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387: 673.
22. Jaster R, Bittorf T, Klinken SP, et al. Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 1996; 51: 1181.
23. James MJ, Zomerdijk JC. Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients. J Biol Chem 2004; 279: 8911.
24. Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: Role of insulin like growth factor 1. Blood 1991; 78: 2823.
25. Ratajczak J, Zhang Q, Pertusini E, et al. The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions - Comparison to other cytokines and growth factors. Leukemia 1998; 12: 371.
26. Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006; 82: 908.
27. Thaunat O, Beaumont C, Chatenoud L, et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005; 80: 1212.
28. Gaston RS, Julian BA, Barker CV, et al. Enalapril: Safe and effective therapy for posttransplant erythrocytosis. Transplant Proc 1993; 25: 1029.